US20020035145A1 - Methods for treating neuropsychiatric disorders - Google Patents
Methods for treating neuropsychiatric disorders Download PDFInfo
- Publication number
- US20020035145A1 US20020035145A1 US09/834,351 US83435101A US2002035145A1 US 20020035145 A1 US20020035145 A1 US 20020035145A1 US 83435101 A US83435101 A US 83435101A US 2002035145 A1 US2002035145 A1 US 2002035145A1
- Authority
- US
- United States
- Prior art keywords
- cycloserine
- alanine
- salt
- serine
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- Schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder are examples of neuropsychiatric disorders.
- Autism for example, is a developmental mental disorder characterized by autistic behavior, social failure, and language delay.
- Alzheimer's Disease is a form of dementia that typically involves progressive mental deterioration, manifested by memory loss, confusion, and disorientation.
- Alzheimer's Disease typically is treated by acetylcholine esterase inhibitors such as tacrine hydrochloride or donepezil.
- Attention Deficit Disorder is a disorder that is most prevalent in children and is associated with increased motor activity and a decreased attention span. Attention Deficit Disorder commonly is treated by administration of psychostimulants such as Ritalin or Dexedrin.
- Depression is a clinical syndrome that includes a persistent sad mood or loss of interest in activities, which persists for at least two weeks in the absence of treatment.
- Conventional therapeutics include serotonin uptake inhibitors (e.g., PROZACTM), monoamine oxidase inhibitors, and tricyclic antidepressants.
- schizophrenia represents a group of neuropsychiatric disorders characterized by dysfunctions of the thinking process, such as delusions, hallucinations, and extensive withdrawal of the patient's interests from other people. Approximately one percent of the worldwide population is afflicted with schizophrenia, and this disorder is accompanied by high morbidity and mortality rates.
- Conventional antipsychotic drugs which act on the dopamine D 2 receptor, can be used to treat the positive symptoms of schizophrenia, such as delusion and hallucination.
- conventional antipsychotic drugs and the new atypical antipsychotic drugs, which act on the dopamine D 2 and 5HT 2 serotonin receptor are limited in their ability to treat cognitive deficits and negative symptoms such as affect blunting (i.e., lack of facial expressions), anergia, and social withdrawal.
- the invention derives from the discovery that neuropsychiatric disorders characterized by a deficit in neurotransmission via the NMDA receptor can be alleviated by a compound that acts as an agonist of the glycine site on the NMDA receptor or an inhibitor of glycine uptake.
- the compound is either a partial agonist such as D-cycloserine, which can be used at a dosage of 105-500 mg, or a full agonist (e.g., D-serine or D-alanine) that is selective for the NMDA receptor (compared to the inhibitory glycine receptor and other receptors), or a glycine uptake inhibitor (e.g., N-methylglycine).
- the invention therefore provides new methods for treating neuropsychiatric disorders in patients (i.e., humans).
- disorders that can be treated by the methods of the invention include schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder.
- the methods entail administering to a patient diagnosed as suffering from such a neuropsychiatric disorder a pharmaceutical composition that contains a therapeutically effective amount of an agonist of the glycine site of the NMDA receptor or a glycine uptake inhibitor, which agonist is relatively selective for (a) the glycine site of the NMDA receptor, compared with (b) the inhibitory glycine receptor and other receptors.
- the pharmaceutical composition may include, for example, (i) a therapeutically effective amount of D-alanine (wherein the pharmaceutical composition is substantially free of D-cycloserine) and/or (ii) a therapeutically effective amount of D-serine, and/or (iii) D-cycloserine in an amount of 105-500 mg, and/or (iv) a therapeutically effective amount of N-methylglycine.
- D-serine, D-alanine, D-cycloserine, and/or N-methylglycine can be substituted with a salt, ester, or alkylated form of the amino acid, or a precursor of the amino acid that is converted (e.g., metabolized) into the amino acid in vivo (e.g., D-phosphoserine, L-phosphoserine, or L-phosphoserine, N,N,N-trimethylglycine (betaine), or N,N-dimethylglycine).
- a salt, ester, or alkylated form of the amino acid or a precursor of the amino acid that is converted (e.g., metabolized) into the amino acid in vivo (e.g., D-phosphoserine, L-phosphoserine, or L-phosphoserine, N,N,N-trimethylglycine (betaine), or N,N-dimethylglycine).
- a dosage of 100 ⁇ g to 100 g is suitable for D-alanine, D-serine, and N-methylglycine.
- D-cycloserine is administered at a dosage of 105 to 500 mg.
- D-serine and D-alanine can be administered to the patient simultaneously or sequentially, e.g., by formulating the D-serine and D-alanine as a single pharmaceutical composition or as two or more pharmaceutical compositions.
- the patient can be treated with both D-serine and D-cycloserine, or D-serine and N-methylglycine, or D-alanine and N-methylglycine, or D-cycloserine and N-methylglycine simultaneously or sequentially.
- the pharmaceutical composition is administered to the patient at least once daily for at least one week.
- the pharmaceutical composition can be administered to the patient in more than one dose per day (e.g., 2, 3, or 4 doses).
- the patient is treated for at least one week; typically, the patient is treated for at least several weeks (e.g., at least 4, 6, or 8 weeks) or months (e.g., at least 4, 8, or 12 months). If necessary, the treatment can continue indefinitely to keep the patient's symptoms under control throughout his or her life.
- a pharmaceutical composition containing D-alanine (substantially free of D-cycloserine), D-serine, D-cycloserine and/or N-methylglycine (or a modified version thereof, as described herein) can be administered to a patient suffering from schizophrenia along with, or in sequence with, an art-known drug for treating schizophrenia (e.g., olanzapine, clozapine, haloperidol, and the like).
- D-alanine typically substantially free of D-cycloserine
- D-serine, D-cycloserine and/or N-methylglycine can be used in combination with, or in sequence with, other art-known antipsychotics (e.g., “typical,” “atypical,” and depot antipsychotics for treating schizophrenia and other psychotic conditions), antidepressants (for treating depression), psychostimulants (for treating attention deficit disorder, depression, or learning disorders), or Alzheimer's disease therapeutics (for treating Alzheimer's disease).
- antipsychotics e.g., “typical,” “atypical,” and depot antipsychotics for treating schizophrenia and other psychotic conditions
- antidepressants for treating depression
- psychostimulants for treating attention deficit disorder, depression, or learning disorders
- Alzheimer's disease therapeutics for treating Alzheimer's disease.
- Such pharmaceutical compositions are included within the invention.
- the antipsychotic, antidepressant, psychostimulant, or Alzheimer's disease therapeutic typically is administered at a dosage of 0.25-5000 mg/d (e.g., 5-1000 mg/d)).
- Typical antipsychotics are conventional antipsychotics such as phenothiazine, butryophenones, thioxantheses, dibenzoxazepines, dihydroindolones, and diphenylbutylpiperidines.
- “Atypical” antipsychotics are a new generation of antipsychotics which generally act on the dopamine D 2 and 5HT 2 serotonin receptor and have high levels of efficacy and a benign extrapyramidal symptom side effect profile.
- Examples of typical antipsychotics include Chlorpromazine (5-2.000 mg/d, e.g., 30-800 mg/d), Thioridazine (5-2000 mg/d, e.g., 20-800 mg/d), Mesoridazine (1-1000 mg/d, e.g., 30-400 mg/d), Fluphenazine (0.5-200 mg/d, e.g., 1-40 mg/d), Perphenazine (0.5-300 mg/d, e.g., 10-65 mg/d), Trifluoperazine (0.5-200 mg/d, e.g., 2-40 mg/d), Thiothixene (1-200 mg/d, e.g., 6-60 mg/d), Haloperidol (0.25-500 mg/d, e.g., 1-100 mg/d), Loxapine (1-1000 mg/d e.g., 20-250 mg/d), Molindone (1-1000 mg/d,
- Examples of atypical antipsychotics include Clozapine (5-2000 mg/d, e.g., 12-900 mg/d), Risperidone (0.25-500 mg/d, e.g., 2-16 mg/d), Olanzapine (1-100 mg/d, e.g., 5-10 mg/d), and Quetiapine (1-2000 mg/d, e.g., 50-750 mg/d).
- Depot antipsychotics also can be used, e.g., Haloperidol decanoate (10-1000 mg/month, e.g., 100-450 mg/month), Fluphenazine decanoate (5-1000 mg/month, e.g., 25-150 mg/month), and Fluphenazine enanthate (5-1000 mg/month, e.g., 25-200 mg/month).
- Haloperidol decanoate 10-1000 mg/month, e.g., 100-450 mg/month
- Fluphenazine decanoate 5-1000 mg/month, e.g., 25-150 mg/month
- Fluphenazine enanthate 5-1000 mg/month, e.g., 25-200 mg/month.
- Additional antipsychotics include Butaperazine (0.5-500 mg/d, e.g., 1-200 mg/d), Carphenazine, (0.5-3000 mg/d, e.g., 1-1000 mg/d), Remoxipride (0.5-5000 mg/d, e.g., 1-2000 mg/d), Piperacetazine (0.5-500 mg/d, e.g., 1-2000 mg/d), Sulpiride (0.5-5000 mg/d, e.g., 1-2000 mg/d), and Ziprasidone (0.5-500 mg/d, e.g., 1-200 mg/d).
- Butaperazine 0.5-500 mg/d, e.g., 1-200 mg/d
- Carphenazine 0.5-3000 mg/d, e.g., 1-1000 mg/d
- Remoxipride 0.5-5000 mg/d, e.g., 1-2000 mg/d
- Piperacetazine 0.5-500 mg/d, e.
- antidepressants examples include Amitriptyline (5-1000 mg/d, e.g., 50-300 mg/d), Amoxapine (5-1000 mg/d, e.g., 50-600 mg/d), Bupropion (5-1000 mg/d, e.g., 200-450 mg/d), Bupropion SR (5-1000 mg/d, e.g., 150-400 mg/d), Clomipramine (5-1000 mg/d, e.g., 25-250 mg/d), Desipramine (5-1000 mg/d, e.g., 100-300 mg/d), Doxepin (5-1000 mg/d, e.g., 75-300 mg/d), Fluoxetine (1-200 mg/d, e.g., 20-80 mg/d), Fluvoxamine (5-1000 mg/d, e.g., 50-300 mg/d), Imipramine (5-1000 mg/d, e.g., 75-300 mg/d),
- Psychostimulants that are particularly useful for treating attention deficit disorder include Dextroamphetamine (0.5-200 mg/d, e.g., 5-40 mg/d), Methamphetamine (0.5-200 mg/d, e.g., 5-25 mg/d), Methyaphenidate (0.5-200 mg/d, e.g., 10-40 mg/d), and Pemoline (5-500 g/d, e.g., 37.5-112.5 mg/d).
- Examples of Alzheimer's disease therapeutics that can be used in the invention include Donepezil (0.5-200 mg/d, e.g., 1-100 mg/d) and Tacrine (0.5-1000 mg/d, e.g., 10-500 mg/d).
- the invention also provides pharmaceutical compositions that contain D-alanine (typically substantially free of D-cycloserine), D-serine, D-cycloserine and/or N-methylglycine (or a modified version thereof, as described herein) along with an antipsychotic, antidepressant, psychostimulant, or Alzheimer's disease therapeutic.
- D-alanine typically substantially free of D-cycloserine
- D-serine typically substantially free of D-cycloserine
- D-cycloserine and/or N-methylglycine or a modified version thereof, as described herein
- SANS Scales for the Assessment of Negative Symptoms
- PANSS Positive and Negative Syndrome Scale
- neuropsychiatric disorder refers to a disease having a pathophysiological component of attenuated NMDA receptor-mediated neurotransmission.
- disorders include schizophrenia, Alzheimer's disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder.
- schizophrenia refers to a psychiatric disorder that includes at least two of the following: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, or negative symptoms. Patients can be diagnosed as schizophrenic using the DSM-IV criteria (APA, 1994, Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), Washington, D.C.).
- Alzheimer's Disease refers to a progressive mental deterioration manifested by memory loss, confusion and disorientation beginning in late middle life and typically resulting in death in five to ten years.
- Pathologically, Alzheimer's Disease can be characterized by thickening, conglutination, and distortion of the intracellular neurofibrils, neurofibrillary tangles and senile plaques composed of granular or filamentous argentophilic masses with an amyloid core. Methods for diagnosing Alzheimer's Disease are known in the art.
- NINCDS-ADRDA Alzheimer's Disease and Related Disorders Association
- NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease-and the Alzheimer's Disease and Related Disorders Association
- ADAS-cog Alzheimer's Disease Assessment Scale-cognitive subscale
- autism refers to a state of mental introversion characterized by morbid self-absorption, social failure, language delay, and stereotyped behavior. Patients can be diagnosed as suffering from autism by using the DSM-IV criteria.
- depression refers to a clinical syndrome that includes a persistent sad mood or loss of interest in activities, which lasts for at least two weeks in the absence of treatment.
- the DSM-IV criteria can be used to diagnose patients as suffering from depression.
- Benign forgetfulness refers to a mild tendency to be unable to retrieve or recall information that was once registered, learned, and stored in memory (e.g., an inability to remember where one placed one's keys or parked one's car). Benign forgetfulness typically affects individuals after 40 years of age and can be recognized by standard assessment instruments such as the Wechsler Memory Scale (Russell, 1975, J. Consult Clin. Psychol. 43:800-809).
- childhood learning disorders refers to an impaired ability to learn, as experienced by certain children. Such learning disorders can be diagnosed by using the DSM-IV criteria.
- close head injury refers to a clinical condition after head injury or trauma which condition can be characterized by cognitive and memory impairment. Such a condition can be diagnosed as “amnestic disorder due to a general medical condition” according to DSM-IV.
- the term “attention deficit disorder,” as used herein, refers to a disorder that is most commonly exhibited by children and which can be characterized by increased motor activity and a decreased attention span.
- the DSM-IV criteria can be used to diagnose attention deficit disorder.
- D-serine and D-alanine refer to the D isomers of the amino acids serine and alanine, respectively. As D isomers, rather than L isomers, these amino acids are not naturally found in proteins.
- “Negative” symptoms of schizophrenia include affect blunting, anergia, alogia and social withdrawal, which can be measured using SANS (the Scales for the Assessment of Negative Symptoms; see Andreasen, 1983, Scales for the Assessment of Negative Symptoms ( SANS ), Iowa City, Iowa).
- “Positive” symptoms of schizophrenia include delusion and hallucination, which can be measured using PANSS (the Positive and Negative Syndrome Scale; see Kay et al., 1987, Schizophrenia Bulletin 13:261-276).
- “Cognitive” symptoms of schizophrenia include impairment in obtaining, organizing, and using intellectual knowledge which can be measured by the Positive and Negative Syndrome Scale-cognitive subscale (PANSS-cognitive subscale)(Lindenmayer et al., 1994, J. Nerv. Ment. Dis. 182:631-638) or with cognitive tasks such as the Wisconsin Card Sorting Test.
- PANSS-cognitive subscale Positive and Negative Syndrome Scale-cognitive subscale
- cognitive tasks such as the Wisconsin Card Sorting Test.
- a “full” agonist of the NMDA receptor is a compound that produces a maximal response at full receptor occupancy.
- a “partial” agonist of the NMDA receptor is a compound that produces a lower maximal response at full receptor occupancy than do full agonists.
- a “glycine uptake inhibitor of the NMDA receptor” is a compound that inhibits the re-uptake of glycine and increases the availability of glycine for the NMDA receptor (e.g., N-methylglycine).
- the invention offers several advantages over many art-known methods for treating neuropsychiatric disorders.
- D-serine, D-alanine, and N-methylglycine can produce a desirable reduction in the positive, negative, and cognitive symptoms of schizophrenia.
- clinically significant improvement can be achieved even with patients who are poorly responsive to treatment by conventional antipsychotics.
- no significant side effects were detected after treatment of schizophrenia patients with D-serine, D-alanine, or N-methylglycine.
- conventional antipsychotics typically lead to tardive dyskinesia (irreversible, involuntary movement disorder), extrapyramidal symptoms, and akathesia symptoms.
- the invention provides methods for treating a patient diagnosed as suffering from a neuropsychiatric disorder having a deficit in neurotransmission via the NMDA receptor (e.g., schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder).
- a neuropsychiatric disorder having a deficit in neurotransmission via the NMDA receptor e.g., schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder.
- a variety of methods for diagnosing these disorders are known to those of skill in the art of clinical psychiatry, and any conventional diagnostic method can be used in conjunction with the invention.
- the treatment method of the invention entails administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing a therapeutically effective amount of (i) an agonist of the glycine site of the NMDA receptor, which agonist is relatively selective for (a) the glycine site of the NMDA receptor, compared with (b) an inhibitory glycine receptor or any other receptor, or (ii) a glycine uptake inhibitor.
- suitable pharmaceutical compositions may include (i) D-alanine substantially free of D-cycloserine and/or (ii) D-serine and/or (iii) N-methylglycine.
- D-serine and D-alanine are commercially available (e.g., from Spectrum Quality Products, Inc., Gardena, Calif.). Where D-alanine is used, the pharmaceutical composition is “substantially free” of D-cycloserine, meaning that the composition lacks D-cycloserine, or D-cycloserine is not included at a level sufficient to have a statistically significant effect upon the efficacy of the pharmaceutical composition, as determined by any method (e.g., by comparing PANSS and/or SANS scores before and after treatment of the patient). In general, this means that D-cycloserine is absent from the pharmaceutical composition or present in an amount such that the patient receives less than 0.02 mg/day.
- Treatment includes administering a therapeutically effective amount of a composition containing D-alanine (substantially free of D-cycloserine) and/or D-serine and/or N-methylglycine to a patient in need of such treatment, thereby treating the neuropsychiatric disorder.
- Such compositions typically contain from about 0.1 to 90% by weight (such as 1 to 20% or 1 to 10%) of D-alanine, D-serine, or N-methylglycine in a pharmaceutically acceptable carrier.
- D-serine and/or D-alanine and/or N-methylglycine is administered to the patient at a dosage of 10 mg to 100 g. More typically, D-serine and/or D-alanine and/or N-methylglycine is administered at a dosage of 100 mg to 10 g.
- treatment continues for at least several weeks to several years or life-long as needed.
- a pharmaceutical composition containing D-cycloserine in an amount equivalent to a dosage of 105 to 500 mg/day is administered to a patient in need of such treatment.
- the dosage can be in an amount of 125 to 400 mg, such as 150 to 300 mg (e.g., 175 mg, 200 mg, 225 mg, or 250 mg).
- D-cycloserine (D-4-amino-3-isoxazolidinone) is commercially available from Eli Lilly, Inc. (Indianapolis, Ind.).
- treatment continues for at least one week and can continue for several years or life-long as needed to control the patient's symptoms.
- D-alanine, D-serine, and/or D-cycloserine and/or N-methylglycine can be substituted with a modified version of the amino acid, such as a salt, ester, alkylated form, or a precursor of the amino acid.
- the amino acid can be in the form of a sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, or ammonium salt.
- Such salt forms of D-serine, D-alanine, N-methylglycine and D-cycloserine can be made in accordance with conventional methods (see, e.g., Organic Chemistry, pgs.
- D-serine D-alanine, N-methylglycine and D-cycloserine
- carboxy group of the amino acid can be converted to an ester group by reaction with an alcohol in accordance with standard esterification methods (Id. at 841-843).
- alcohols having 1-20 carbon atoms can be used to produce an ester of D-serine, D-alanine, N-methylglycine or D-cycloserine for use in the invention (e.g., methyl-, ethyl-, propyl-, isopropyl-, butyl-, isobutyl-, sec-butyl-, tert-butyl-, pentyl-, isopentyl-, tert-pentyl-, hexyl-, heptyl-, octyl-, decyl-, dodecyl-, tetradecyl-, hexadecyl-, octadecyl-, and phenyl-alcohols can be used).
- the amino group of the amino acid can be alkylated, using conventional methods, to produce a secondary or tertiary amino group by ammonolysis of halides or reductive amination (Id. at 939-948).
- an alkyl group having 1-20 carbon atoms can be added to the amino acid to produce an alkylated amino acid (e.g., methyl-, ethyl-, propyl-, isopropyl-, butyl-, isobutyl-, sec-butyl-, tert-butyl-, pentyl-, isopentyl-, tert-pentyl-, hexyl-, heptyl-, octyl-, decyl-, dodecyl-, tetradecyl-, hexadecyl-, octadecyl- and phenyl-groups can be added to the amino acid).
- D-phosphoserine and L-phosphoserine are examples of precursors of D-serine, and are commercially available (e.g., from Sigma Chemical, St. Louis, Mo.).
- N,N,N-trimethylglycine (betaine) and N,N-dimethylglycine are examples of precursors of N-methylglycine.
- compositions can be administered to the patient by any, or a combination, of several routes, such as oral, intravenous, trans-mucosal (e.g., nasal, vaginal, etc.), pulmonary, transdermal, ocular, buccal, sublingual, intraperitoneal, intrathecal, intramuscular, or long term depot preparation.
- Solid compositions for oral administration can contain suitable carriers or excipients, such as corn starch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, lipids, alginic acid, or ingredients for controlled slow release.
- Disintegrators that can be used include, without limitation, micro-crystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
- Tablet binders that may be used include, without limitation, acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch, and ethylcellulose.
- Liquid compositions for oral administration prepared in water or other aqueous vehicles can include solutions, emulsions, syrups, and elixirs containing, together with the active compound(s), wetting agents, sweeteners, coloring agents, and flavoring agents.
- Various liquid and powder compositions can be prepared by conventional methods for inhalation into the lungs of the patient to be treated.
- Injectable compositions may contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).
- the compounds may be administered by the drip method, whereby a pharmaceutical composition containing the active compound(s) and a physiologically acceptable excipient is infused.
- Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients.
- a sterile composition of a suitable soluble salt form of the compound can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution, or depot forms of the compounds (e.g., decanoate, palmitate, undecylenic, enanthate) can be dissolved in sesame oil.
- a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution
- depot forms of the compounds e.g., decanoate, palmitate, undecylenic, enanthate
- the pharmaceutical composition can be formulated as a chewing gum, lollipop, or the like.
- This study employed 37 patients who were diagnosed as having schizophrenia. All patients fulfilled the DSM-IV diagnosis of schizophrenia (APA, 1994, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington, D.C.). All of the patients also fulfilled the criteria of primary deficit syndrome, with a SANS score of more than 40 (Kirkpatrick et al., 1989, Psychiatry Research 30:119-123; Andreasen, 1983, Scales for the Assessment of Negative Symptoms ( SANS ), Iowa City, Iowa). All of the patients were poorly responsive to treatment by other antipsychotic drugs, and had been kept on a stable dose of an antipsychotic drug for at least 3 months prior to enrollment in this study.
- the Simpson-Angus Scale was used to measure extrapyramidal symptoms (EPS; Simpson et al., 1970, Acta Psychiatrica Scandinavia Suppl. 212:11-19).
- the Abnormal Involuntary Movement Scale (AIMS) was used to measure dyskinesia (Simpson et al., 1970, Acta Psychiatrica Scandinavia Suppl. 212:11-19).
- the Barnes Scale was used to measure akathesia (Barnes, 1989, Brit. J. Psychiatry 154:672-676).
- Treatment with D-alanine resulted in an 11% reduction of the negative symptoms and a 12% reduction of the positive symptoms.
- Treatment with N-methylglycine resulted in a 20% reduction of the negative symptoms and a 15% reduction of the positive symptoms. These reductions in the negative and positive symptoms represented clinically significant improvement.
- Treatment with each of D-serine, D-alanine, and N-methylglycine also improved cognition, as measured using the PANSS-cognitive subscale and the Wisconsin Card Sort Test. These results indicate that D-serine, D-alanine, and N-methylglycine are effective in treating schizophrenia even in patients who are poorly responsive to treatment by conventional antipsychotic drugs.
- D-serine, D-alanine, or N-methylglycine offer an advantage over many conventional drugs for treating schizophrenia in that they do not cause significant side effects.
Abstract
Description
- This application claims priority under 35 U.S.C. §119(e) from provisional application U.S. Ser. No. 60/081,645, filed Apr. 14, 1998.
- Schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder are examples of neuropsychiatric disorders. Autism, for example, is a developmental mental disorder characterized by autistic behavior, social failure, and language delay. Alzheimer's Disease is a form of dementia that typically involves progressive mental deterioration, manifested by memory loss, confusion, and disorientation. Alzheimer's Disease typically is treated by acetylcholine esterase inhibitors such as tacrine hydrochloride or donepezil. Attention Deficit Disorder is a disorder that is most prevalent in children and is associated with increased motor activity and a decreased attention span. Attention Deficit Disorder commonly is treated by administration of psychostimulants such as Ritalin or Dexedrin. Depression is a clinical syndrome that includes a persistent sad mood or loss of interest in activities, which persists for at least two weeks in the absence of treatment. Conventional therapeutics include serotonin uptake inhibitors (e.g., PROZAC™), monoamine oxidase inhibitors, and tricyclic antidepressants.
- The term schizophrenia represents a group of neuropsychiatric disorders characterized by dysfunctions of the thinking process, such as delusions, hallucinations, and extensive withdrawal of the patient's interests from other people. Approximately one percent of the worldwide population is afflicted with schizophrenia, and this disorder is accompanied by high morbidity and mortality rates.
- Conventional antipsychotic drugs, which act on the dopamine D2 receptor, can be used to treat the positive symptoms of schizophrenia, such as delusion and hallucination. In general, conventional antipsychotic drugs and the new atypical antipsychotic drugs, which act on the dopamine D2 and 5HT2 serotonin receptor, are limited in their ability to treat cognitive deficits and negative symptoms such as affect blunting (i.e., lack of facial expressions), anergia, and social withdrawal.
- The invention derives from the discovery that neuropsychiatric disorders characterized by a deficit in neurotransmission via the NMDA receptor can be alleviated by a compound that acts as an agonist of the glycine site on the NMDA receptor or an inhibitor of glycine uptake. The compound is either a partial agonist such as D-cycloserine, which can be used at a dosage of 105-500 mg, or a full agonist (e.g., D-serine or D-alanine) that is selective for the NMDA receptor (compared to the inhibitory glycine receptor and other receptors), or a glycine uptake inhibitor (e.g., N-methylglycine). The invention therefore provides new methods for treating neuropsychiatric disorders in patients (i.e., humans). Examples of disorders that can be treated by the methods of the invention include schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as suffering from such a neuropsychiatric disorder a pharmaceutical composition that contains a therapeutically effective amount of an agonist of the glycine site of the NMDA receptor or a glycine uptake inhibitor, which agonist is relatively selective for (a) the glycine site of the NMDA receptor, compared with (b) the inhibitory glycine receptor and other receptors. The pharmaceutical composition may include, for example, (i) a therapeutically effective amount of D-alanine (wherein the pharmaceutical composition is substantially free of D-cycloserine) and/or (ii) a therapeutically effective amount of D-serine, and/or (iii) D-cycloserine in an amount of 105-500 mg, and/or (iv) a therapeutically effective amount of N-methylglycine.
- In variations of the methods described herein, D-serine, D-alanine, D-cycloserine, and/or N-methylglycine can be substituted with a salt, ester, or alkylated form of the amino acid, or a precursor of the amino acid that is converted (e.g., metabolized) into the amino acid in vivo (e.g., D-phosphoserine, L-phosphoserine, or L-phosphoserine, N,N,N-trimethylglycine (betaine), or N,N-dimethylglycine).
- Typically, a dosage of 100 μg to 100 g (e.g., 1 mg to 100 g; 1 mg to 100 mg; 10 mg to 100 g; 10 mg to 10 g; or 10 to 500 mg) is suitable for D-alanine, D-serine, and N-methylglycine. D-cycloserine is administered at a dosage of 105 to 500 mg. When the patient is treated with both D-serine and D-alanine, D-serine and D-alanine can be administered to the patient simultaneously or sequentially, e.g., by formulating the D-serine and D-alanine as a single pharmaceutical composition or as two or more pharmaceutical compositions. Likewise, the patient can be treated with both D-serine and D-cycloserine, or D-serine and N-methylglycine, or D-alanine and N-methylglycine, or D-cycloserine and N-methylglycine simultaneously or sequentially. In one, but not the only, suitable method of treatment, the pharmaceutical composition is administered to the patient at least once daily for at least one week. If desired, the pharmaceutical composition can be administered to the patient in more than one dose per day (e.g., 2, 3, or 4 doses). Generally, the patient is treated for at least one week; typically, the patient is treated for at least several weeks (e.g., at least 4, 6, or 8 weeks) or months (e.g., at least 4, 8, or 12 months). If necessary, the treatment can continue indefinitely to keep the patient's symptoms under control throughout his or her life.
- If desired, a pharmaceutical composition containing D-alanine (substantially free of D-cycloserine), D-serine, D-cycloserine and/or N-methylglycine (or a modified version thereof, as described herein) can be administered to a patient suffering from schizophrenia along with, or in sequence with, an art-known drug for treating schizophrenia (e.g., olanzapine, clozapine, haloperidol, and the like). Similarly, D-alanine (typically substantially free of D-cycloserine), D-serine, D-cycloserine and/or N-methylglycine (or a modified version thereof, as described herein) can be used in combination with, or in sequence with, other art-known antipsychotics (e.g., “typical,” “atypical,” and depot antipsychotics for treating schizophrenia and other psychotic conditions), antidepressants (for treating depression), psychostimulants (for treating attention deficit disorder, depression, or learning disorders), or Alzheimer's disease therapeutics (for treating Alzheimer's disease). Such pharmaceutical compositions are included within the invention. In general, the antipsychotic, antidepressant, psychostimulant, or Alzheimer's disease therapeutic typically is administered at a dosage of 0.25-5000 mg/d (e.g., 5-1000 mg/d)). “Typical” antipsychotics are conventional antipsychotics such as phenothiazine, butryophenones, thioxantheses, dibenzoxazepines, dihydroindolones, and diphenylbutylpiperidines. “Atypical” antipsychotics are a new generation of antipsychotics which generally act on the dopamine D2 and 5HT2 serotonin receptor and have high levels of efficacy and a benign extrapyramidal symptom side effect profile. Examples of typical antipsychotics (and examples of suitable daily (d) dosages) include Chlorpromazine (5-2.000 mg/d, e.g., 30-800 mg/d), Thioridazine (5-2000 mg/d, e.g., 20-800 mg/d), Mesoridazine (1-1000 mg/d, e.g., 30-400 mg/d), Fluphenazine (0.5-200 mg/d, e.g., 1-40 mg/d), Perphenazine (0.5-300 mg/d, e.g., 10-65 mg/d), Trifluoperazine (0.5-200 mg/d, e.g., 2-40 mg/d), Thiothixene (1-200 mg/d, e.g., 6-60 mg/d), Haloperidol (0.25-500 mg/d, e.g., 1-100 mg/d), Loxapine (1-1000 mg/d e.g., 20-250 mg/d), Molindone (1-1000 mg/d, e.g., 15-225 mg/d), Acetophenazine (10-2000 mg/d, e.g., 30-500 mg/d), Chlorprothixene (5-2000 mg/d, e.g., 30-500 mg/d), Droperidol (0.25-500 mg/d, e.g., 1-100 mg/d), Pimozide (0.25-500 mg/d, e.g., 1-100 mg/d). Examples of atypical antipsychotics (and examples of suitable daily dosages) include Clozapine (5-2000 mg/d, e.g., 12-900 mg/d), Risperidone (0.25-500 mg/d, e.g., 2-16 mg/d), Olanzapine (1-100 mg/d, e.g., 5-10 mg/d), and Quetiapine (1-2000 mg/d, e.g., 50-750 mg/d). Depot antipsychotics also can be used, e.g., Haloperidol decanoate (10-1000 mg/month, e.g., 100-450 mg/month), Fluphenazine decanoate (5-1000 mg/month, e.g., 25-150 mg/month), and Fluphenazine enanthate (5-1000 mg/month, e.g., 25-200 mg/month). Additional antipsychotics include Butaperazine (0.5-500 mg/d, e.g., 1-200 mg/d), Carphenazine, (0.5-3000 mg/d, e.g., 1-1000 mg/d), Remoxipride (0.5-5000 mg/d, e.g., 1-2000 mg/d), Piperacetazine (0.5-500 mg/d, e.g., 1-2000 mg/d), Sulpiride (0.5-5000 mg/d, e.g., 1-2000 mg/d), and Ziprasidone (0.5-500 mg/d, e.g., 1-200 mg/d). Examples of antidepressants that can be used include Amitriptyline (5-1000 mg/d, e.g., 50-300 mg/d), Amoxapine (5-1000 mg/d, e.g., 50-600 mg/d), Bupropion (5-1000 mg/d, e.g., 200-450 mg/d), Bupropion SR (5-1000 mg/d, e.g., 150-400 mg/d), Clomipramine (5-1000 mg/d, e.g., 25-250 mg/d), Desipramine (5-1000 mg/d, e.g., 100-300 mg/d), Doxepin (5-1000 mg/d, e.g., 75-300 mg/d), Fluoxetine (1-200 mg/d, e.g., 20-80 mg/d), Fluvoxamine (5-1000 mg/d, e.g., 50-300 mg/d), Imipramine (5-1000 mg/d, e.g., 75-300 mg/d), Maprotiline (5-1000, e.g., 75-225 mg/d), Mirtazapine (1-200 mg/d, e.g., 15-45 mg/d), Nefazodone (5-1000 mg/d, e.g., 200-600 mg/d), Nortriptyline (5-1000 mg/d, e.g., 75-150 mg/d), Paroxetine (1-200 mg/d, e.g., 10-60 mg/d), Pheneizine (1-500 mg/d, e.g., 5-90 mg/d), Protriptyline (1-200 mg/d, e.g., 15-60 mg/d), Sertraline (5-1000 mg/d, e.g., 50-200 mg/d), Tranylcypromine (1-200 mg/d, e.g., 30-60 mg/d), Trazodone (5-1000 mg/d, e.g., 150-600 mg/d), Trimipramine (5-1000 mg/d, e.g., 5-300 mg/d), Venlafaxine (5-1000 mg/d, e.g., 75-375 mg/d), and Venlafaxine XR (5-1000 mg/d, e.g, 75-375 mg/d). Psychostimulants that are particularly useful for treating attention deficit disorder include Dextroamphetamine (0.5-200 mg/d, e.g., 5-40 mg/d), Methamphetamine (0.5-200 mg/d, e.g., 5-25 mg/d), Methyaphenidate (0.5-200 mg/d, e.g., 10-40 mg/d), and Pemoline (5-500 g/d, e.g., 37.5-112.5 mg/d). Examples of Alzheimer's disease therapeutics that can be used in the invention include Donepezil (0.5-200 mg/d, e.g., 1-100 mg/d) and Tacrine (0.5-1000 mg/d, e.g., 10-500 mg/d). Thus, the invention also provides pharmaceutical compositions that contain D-alanine (typically substantially free of D-cycloserine), D-serine, D-cycloserine and/or N-methylglycine (or a modified version thereof, as described herein) along with an antipsychotic, antidepressant, psychostimulant, or Alzheimer's disease therapeutic.
- If desired, one can measure negative and/or positive and/or cognitive symptom(s) of schizophrenia before and after treatment of the patient. A reduction in such a symptom indicates that the patient's condition has improved. Improvement in the symptoms of schizophrenia can be assessed using the Scales for the Assessment of Negative Symptoms (SANS) or Positive and Negative Syndrome Scale (PANSS) (see, e.g., Andreasen, 1983,Scales for the Assessment of Negative Symptoms (SANS), Iowa City, Iowa and Kay et al., 1987, Schizophrenia Bulletin 13:261-276). Likewise, one can measure improvement of other neuropsychiatric disorders in patients who have been treated by the methods of the invention.
- As used herein, the term “neuropsychiatric disorder” refers to a disease having a pathophysiological component of attenuated NMDA receptor-mediated neurotransmission. Examples of such disorders include schizophrenia, Alzheimer's disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder.
- As used herein, the term “schizophrenia” refers to a psychiatric disorder that includes at least two of the following: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, or negative symptoms. Patients can be diagnosed as schizophrenic using the DSM-IV criteria (APA, 1994,Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), Washington, D.C.).
- The term “Alzheimer's Disease” refers to a progressive mental deterioration manifested by memory loss, confusion and disorientation beginning in late middle life and typically resulting in death in five to ten years. Pathologically, Alzheimer's Disease can be characterized by thickening, conglutination, and distortion of the intracellular neurofibrils, neurofibrillary tangles and senile plaques composed of granular or filamentous argentophilic masses with an amyloid core. Methods for diagnosing Alzheimer's Disease are known in the art. For example, the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease-and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria can be used to diagnose Alzheimer's Disease (McKhann et al., 1984, Neurology 34:939-944). The patient's cognitive function can be assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog; Rosen et al., 1984, Am. J. Psychiatry 141:1356-1364).
- As used herein, the term “autism” refers to a state of mental introversion characterized by morbid self-absorption, social failure, language delay, and stereotyped behavior. Patients can be diagnosed as suffering from autism by using the DSM-IV criteria.
- As used herein, the term “depression” refers to a clinical syndrome that includes a persistent sad mood or loss of interest in activities, which lasts for at least two weeks in the absence of treatment. The DSM-IV criteria can be used to diagnose patients as suffering from depression.
- The term “benign forgetfulness,” as used herein, refers to a mild tendency to be unable to retrieve or recall information that was once registered, learned, and stored in memory (e.g., an inability to remember where one placed one's keys or parked one's car). Benign forgetfulness typically affects individuals after 40 years of age and can be recognized by standard assessment instruments such as the Wechsler Memory Scale (Russell, 1975, J. Consult Clin. Psychol. 43:800-809).
- As used herein, the term “childhood learning disorders” refers to an impaired ability to learn, as experienced by certain children. Such learning disorders can be diagnosed by using the DSM-IV criteria.
- The term “close head injury,” as used herein, refers to a clinical condition after head injury or trauma which condition can be characterized by cognitive and memory impairment. Such a condition can be diagnosed as “amnestic disorder due to a general medical condition” according to DSM-IV.
- The term “attention deficit disorder,” as used herein, refers to a disorder that is most commonly exhibited by children and which can be characterized by increased motor activity and a decreased attention span. The DSM-IV criteria can be used to diagnose attention deficit disorder.
- The terms “D-serine” and “D-alanine” refer to the D isomers of the amino acids serine and alanine, respectively. As D isomers, rather than L isomers, these amino acids are not naturally found in proteins.
- “Negative” symptoms of schizophrenia include affect blunting, anergia, alogia and social withdrawal, which can be measured using SANS (the Scales for the Assessment of Negative Symptoms; see Andreasen, 1983,Scales for the Assessment of Negative Symptoms (SANS), Iowa City, Iowa).
- “Positive” symptoms of schizophrenia include delusion and hallucination, which can be measured using PANSS (the Positive and Negative Syndrome Scale; see Kay et al., 1987, Schizophrenia Bulletin 13:261-276).
- “Cognitive” symptoms of schizophrenia include impairment in obtaining, organizing, and using intellectual knowledge which can be measured by the Positive and Negative Syndrome Scale-cognitive subscale (PANSS-cognitive subscale)(Lindenmayer et al., 1994, J. Nerv. Ment. Dis. 182:631-638) or with cognitive tasks such as the Wisconsin Card Sorting Test.
- A “full” agonist of the NMDA receptor is a compound that produces a maximal response at full receptor occupancy.
- A “partial” agonist of the NMDA receptor is a compound that produces a lower maximal response at full receptor occupancy than do full agonists.
- A “glycine uptake inhibitor of the NMDA receptor” is a compound that inhibits the re-uptake of glycine and increases the availability of glycine for the NMDA receptor (e.g., N-methylglycine).
- The invention offers several advantages over many art-known methods for treating neuropsychiatric disorders. For example, unlike many conventional antipsychotic therapeutics, D-serine, D-alanine, and N-methylglycine can produce a desirable reduction in the positive, negative, and cognitive symptoms of schizophrenia. As shown by the examples set forth below, clinically significant improvement can be achieved even with patients who are poorly responsive to treatment by conventional antipsychotics. In addition, no significant side effects were detected after treatment of schizophrenia patients with D-serine, D-alanine, or N-methylglycine. In contrast, conventional antipsychotics typically lead to tardive dyskinesia (irreversible, involuntary movement disorder), extrapyramidal symptoms, and akathesia symptoms.
- Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
- The invention provides methods for treating a patient diagnosed as suffering from a neuropsychiatric disorder having a deficit in neurotransmission via the NMDA receptor (e.g., schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder). As described above, a variety of methods for diagnosing these disorders are known to those of skill in the art of clinical psychiatry, and any conventional diagnostic method can be used in conjunction with the invention.
- The treatment method of the invention entails administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing a therapeutically effective amount of (i) an agonist of the glycine site of the NMDA receptor, which agonist is relatively selective for (a) the glycine site of the NMDA receptor, compared with (b) an inhibitory glycine receptor or any other receptor, or (ii) a glycine uptake inhibitor. For example, suitable pharmaceutical compositions may include (i) D-alanine substantially free of D-cycloserine and/or (ii) D-serine and/or (iii) N-methylglycine. D-serine and D-alanine are commercially available (e.g., from Spectrum Quality Products, Inc., Gardena, Calif.). Where D-alanine is used, the pharmaceutical composition is “substantially free” of D-cycloserine, meaning that the composition lacks D-cycloserine, or D-cycloserine is not included at a level sufficient to have a statistically significant effect upon the efficacy of the pharmaceutical composition, as determined by any method (e.g., by comparing PANSS and/or SANS scores before and after treatment of the patient). In general, this means that D-cycloserine is absent from the pharmaceutical composition or present in an amount such that the patient receives less than 0.02 mg/day.
- Treatment includes administering a therapeutically effective amount of a composition containing D-alanine (substantially free of D-cycloserine) and/or D-serine and/or N-methylglycine to a patient in need of such treatment, thereby treating the neuropsychiatric disorder. Such compositions typically contain from about 0.1 to 90% by weight (such as 1 to 20% or 1 to 10%) of D-alanine, D-serine, or N-methylglycine in a pharmaceutically acceptable carrier. Regardless of the concentration of D-serine or D-alanine in the pharmaceutical composition, D-serine and/or D-alanine and/or N-methylglycine is administered to the patient at a dosage of 10 mg to 100 g. More typically, D-serine and/or D-alanine and/or N-methylglycine is administered at a dosage of 100 mg to 10 g. Generally, treatment continues for at least several weeks to several years or life-long as needed.
- In an alternative method for treating a neuropsychiatric disorder in a patient, a pharmaceutical composition containing D-cycloserine in an amount equivalent to a dosage of 105 to 500 mg/day is administered to a patient in need of such treatment. For example, the dosage can be in an amount of 125 to 400 mg, such as 150 to 300 mg (e.g., 175 mg, 200 mg, 225 mg, or 250 mg). D-cycloserine (D-4-amino-3-isoxazolidinone) is commercially available from Eli Lilly, Inc. (Indianapolis, Ind.). Generally, treatment continues for at least one week and can continue for several years or life-long as needed to control the patient's symptoms.
- In all of the methods of the invention, D-alanine, D-serine, and/or D-cycloserine and/or N-methylglycine can be substituted with a modified version of the amino acid, such as a salt, ester, alkylated form, or a precursor of the amino acid. For example, the amino acid can be in the form of a sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, or ammonium salt. Such salt forms of D-serine, D-alanine, N-methylglycine and D-cycloserine can be made in accordance with conventional methods (see, e.g.,Organic Chemistry, pgs. 822-823, Morrison and Boyd, ed., Fifth Edition, Allyn and Bacon, Inc., Newton, Mass.). Other modified forms of D-serine, D-alanine, N-methylglycine and D-cycloserine also can be used in the methods of the invention. For example, the carboxy group of the amino acid can be converted to an ester group by reaction with an alcohol in accordance with standard esterification methods (Id. at 841-843). For example, alcohols having 1-20 carbon atoms can be used to produce an ester of D-serine, D-alanine, N-methylglycine or D-cycloserine for use in the invention (e.g., methyl-, ethyl-, propyl-, isopropyl-, butyl-, isobutyl-, sec-butyl-, tert-butyl-, pentyl-, isopentyl-, tert-pentyl-, hexyl-, heptyl-, octyl-, decyl-, dodecyl-, tetradecyl-, hexadecyl-, octadecyl-, and phenyl-alcohols can be used). In another variation, the amino group of the amino acid can be alkylated, using conventional methods, to produce a secondary or tertiary amino group by ammonolysis of halides or reductive amination (Id. at 939-948). For example, an alkyl group having 1-20 carbon atoms can be added to the amino acid to produce an alkylated amino acid (e.g., methyl-, ethyl-, propyl-, isopropyl-, butyl-, isobutyl-, sec-butyl-, tert-butyl-, pentyl-, isopentyl-, tert-pentyl-, hexyl-, heptyl-, octyl-, decyl-, dodecyl-, tetradecyl-, hexadecyl-, octadecyl- and phenyl-groups can be added to the amino acid). D-phosphoserine and L-phosphoserine are examples of precursors of D-serine, and are commercially available (e.g., from Sigma Chemical, St. Louis, Mo.). N,N,N-trimethylglycine (betaine) and N,N-dimethylglycine are examples of precursors of N-methylglycine.
- In all of the methods of the invention, appropriate dosages of D-alanine, D-serine, D-cycloserine, or N-methylglycine (or modified versions thereof) can readily be determined by those of ordinary skill in the art of medicine by monitoring the patient for signs of disease amelioration or inhibition, and increasing or decreasing the dosage and/or frequency of treatment as desired.
- The pharmaceutical compositions can be administered to the patient by any, or a combination, of several routes, such as oral, intravenous, trans-mucosal (e.g., nasal, vaginal, etc.), pulmonary, transdermal, ocular, buccal, sublingual, intraperitoneal, intrathecal, intramuscular, or long term depot preparation. Solid compositions for oral administration can contain suitable carriers or excipients, such as corn starch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, lipids, alginic acid, or ingredients for controlled slow release. Disintegrators that can be used include, without limitation, micro-crystalline cellulose, corn starch, sodium starch glycolate and alginic acid. Tablet binders that may be used include, without limitation, acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch, and ethylcellulose.
- Liquid compositions for oral administration prepared in water or other aqueous vehicles can include solutions, emulsions, syrups, and elixirs containing, together with the active compound(s), wetting agents, sweeteners, coloring agents, and flavoring agents. Various liquid and powder compositions can be prepared by conventional methods for inhalation into the lungs of the patient to be treated.
- Injectable compositions may contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like). For intravenous injections, the compounds may be administered by the drip method, whereby a pharmaceutical composition containing the active compound(s) and a physiologically acceptable excipient is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. For intramuscular preparations, a sterile composition of a suitable soluble salt form of the compound can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution, or depot forms of the compounds (e.g., decanoate, palmitate, undecylenic, enanthate) can be dissolved in sesame oil. Alternatively, the pharmaceutical composition can be formulated as a chewing gum, lollipop, or the like.
- The following examples demonstrate that D-alanine, D-serine, and N-methylglycine each can be used to treat a neuropsychiatric disorder in patients.
- Patients
- This study employed 37 patients who were diagnosed as having schizophrenia. All patients fulfilled the DSM-IV diagnosis of schizophrenia (APA, 1994, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington, D.C.). All of the patients also fulfilled the criteria of primary deficit syndrome, with a SANS score of more than 40 (Kirkpatrick et al., 1989, Psychiatry Research 30:119-123; Andreasen, 1983,Scales for the Assessment of Negative Symptoms (SANS), Iowa City, Iowa). All of the patients were poorly responsive to treatment by other antipsychotic drugs, and had been kept on a stable dose of an antipsychotic drug for at least 3 months prior to enrollment in this study.
- Assessments
- Several scales were used to assess the severity of the disorder in each patient. At the beginning of the study (i.e., the baseline), the PANSS, SANS, and Global Assessment Scales (CGI) were used. Each scale also was completed at the end of each 2-week period throughout the study. These assessments were performed by a psychiatrist who was blind to the treatment assignment. The Wisconsin Card Sort Test was used to provide a cognitive rating of the patients; in general, schizophrenic patients perform poorly on this test. The Wisconsin Card Sort Test was administered only at the initiation of the study and at the end of the 6-week study. To measure side effects, the Simpson-Angus Scale was used to measure extrapyramidal symptoms (EPS; Simpson et al., 1970, Acta Psychiatrica Scandinavia Suppl. 212:11-19). The Abnormal Involuntary Movement Scale (AIMS) was used to measure dyskinesia (Simpson et al., 1970, Acta Psychiatrica Scandinavia Suppl. 212:11-19). The Barnes Scale was used to measure akathesia (Barnes, 1989, Brit. J. Psychiatry 154:672-676). The side effects of D-serine, D-alanine, and N-methylglycine treatments were assessed biweekly according to the UKU side effects rating scale (Scandinavian Society of Psychopharmacology Committee of Clinical Investigation: The UKU side effect rating scale: scale for the registration of unwanted effects of psychotropics. Acta. Psychiatr. Scand. 1987; Suppl. 334:81-94).
- Treatment and Results
- Using double-blind conditions, the patients were randomly assigned to receive placebo (fruit juice), D-serine (30 mg/kg/day), D-alanine (60-100 mg/kg/day), or N-methylglycine (30 mg/kg/day) once a day by mouth for a period of 6 weeks. As indicated by the results shown in Table 1, treatment with D-serine, D-alanine, or N-methylglycine improved the schizophrenic symptoms and cognitive deficit of the patients. More specifically, treatment with D-serine resulted in a 21% reduction of the negative symptoms (on the SANS scale), and it resulted in a 17% reduction of the positive symptoms (on the PANSS-positive subscale). Treatment with D-alanine resulted in an 11% reduction of the negative symptoms and a 12% reduction of the positive symptoms. Treatment with N-methylglycine resulted in a 20% reduction of the negative symptoms and a 15% reduction of the positive symptoms. These reductions in the negative and positive symptoms represented clinically significant improvement. Treatment with each of D-serine, D-alanine, and N-methylglycine also improved cognition, as measured using the PANSS-cognitive subscale and the Wisconsin Card Sort Test. These results indicate that D-serine, D-alanine, and N-methylglycine are effective in treating schizophrenia even in patients who are poorly responsive to treatment by conventional antipsychotic drugs.
- Using the UKU scale for rating side effects, no side effects were noted after treatment with D-serine, D-alanine, or N-methylglycine. In addition, there was no newly emergent tardive dyskinesia or worsening of extrapyramidal or akathesia symptoms. Thus, D-serine, D-alanine, and N-methylglycine offer an advantage over many conventional drugs for treating schizophrenia in that they do not cause significant side effects.
TABLE 1 Effects of D-serine, D-alanine, and N-methylglycine Treatment on Schizophrenia Patients D-serine D-alanine N-methylglycine Placebo Clinical Symptoms Negative −21%* −12%* −20%* −1% Symptoms Positive −17%* −11%* −15%* 3% Symptoms CGI 4.8->2.6* 3.9->2.8* 4.2->2.7* 4.5->4.0 Cognition Cognitive −12%* −11%* −12%* 1% symptoms WCST +0.9 +0.5* +0.7* −0.5 (category)* Side Effects EPS 1.4-->1.7 3.1-->3.1 2.1-->2.1 3.3-->3.4 AIMS 0.3-->0.3 0.5-->0.1 0.4-->0.3 0.5-->0.9 Barnes 0.4-->0.8 0.4-->0.6 0.5-->0.6 0.9-->0.9 - It is to be understood that, while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (38)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/834,351 US6420351B1 (en) | 1998-04-14 | 2001-04-13 | Methods for treating neuropsychiatric disorders |
US10/196,686 US6667297B2 (en) | 1998-04-14 | 2002-07-15 | Methods for treating neuropsychiatric disorders |
US10/668,583 US6974821B2 (en) | 1998-04-14 | 2003-09-23 | Methods for treating neuropsychiatric disorders |
US11/175,832 US7704978B2 (en) | 1998-04-14 | 2005-07-05 | Methods for treating neuropsychiatric disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8164598P | 1998-04-14 | 1998-04-14 | |
US09/291,296 US6228875B1 (en) | 1998-04-14 | 1999-04-14 | Methods for treating neuropsychiatric disorders |
US09/834,351 US6420351B1 (en) | 1998-04-14 | 2001-04-13 | Methods for treating neuropsychiatric disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/291,296 Continuation US6228875B1 (en) | 1998-04-14 | 1999-04-14 | Methods for treating neuropsychiatric disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/196,686 Continuation US6667297B2 (en) | 1998-04-14 | 2002-07-15 | Methods for treating neuropsychiatric disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020035145A1 true US20020035145A1 (en) | 2002-03-21 |
US6420351B1 US6420351B1 (en) | 2002-07-16 |
Family
ID=22165468
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/291,296 Expired - Lifetime US6228875B1 (en) | 1998-04-14 | 1999-04-14 | Methods for treating neuropsychiatric disorders |
US09/834,351 Expired - Lifetime US6420351B1 (en) | 1998-04-14 | 2001-04-13 | Methods for treating neuropsychiatric disorders |
US10/196,686 Expired - Lifetime US6667297B2 (en) | 1998-04-14 | 2002-07-15 | Methods for treating neuropsychiatric disorders |
US10/668,583 Expired - Lifetime US6974821B2 (en) | 1998-04-14 | 2003-09-23 | Methods for treating neuropsychiatric disorders |
US11/175,832 Expired - Lifetime US7704978B2 (en) | 1998-04-14 | 2005-07-05 | Methods for treating neuropsychiatric disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/291,296 Expired - Lifetime US6228875B1 (en) | 1998-04-14 | 1999-04-14 | Methods for treating neuropsychiatric disorders |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/196,686 Expired - Lifetime US6667297B2 (en) | 1998-04-14 | 2002-07-15 | Methods for treating neuropsychiatric disorders |
US10/668,583 Expired - Lifetime US6974821B2 (en) | 1998-04-14 | 2003-09-23 | Methods for treating neuropsychiatric disorders |
US11/175,832 Expired - Lifetime US7704978B2 (en) | 1998-04-14 | 2005-07-05 | Methods for treating neuropsychiatric disorders |
Country Status (17)
Country | Link |
---|---|
US (5) | US6228875B1 (en) |
EP (3) | EP2338482A3 (en) |
JP (1) | JP2002511409A (en) |
AT (1) | ATE369848T1 (en) |
AU (1) | AU765603C (en) |
CA (2) | CA2601132C (en) |
CY (1) | CY1106898T1 (en) |
DE (2) | DE1073432T1 (en) |
DK (1) | DK1073432T3 (en) |
ES (1) | ES2164040T3 (en) |
HK (1) | HK1036583A1 (en) |
HU (1) | HUP0101627A3 (en) |
IL (1) | IL139008A0 (en) |
NZ (1) | NZ508160A (en) |
PT (1) | PT1073432E (en) |
RU (1) | RU2219924C2 (en) |
WO (1) | WO1999052519A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158230A1 (en) * | 2001-12-28 | 2003-08-21 | Rakefet Cohen | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
US20030185754A1 (en) * | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
US20030235177A1 (en) * | 2002-06-19 | 2003-12-25 | Yeon-Chun Park | Composite access point apparatus, and method for processing voice/data packets using the same |
US20040087596A1 (en) * | 2002-09-13 | 2004-05-06 | Schneider Jay S. | Methods and kit for treating Parkinson's disease |
US20050118286A1 (en) * | 2003-10-30 | 2005-06-02 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US20050159790A1 (en) * | 2000-05-08 | 2005-07-21 | Brainsgate Ltd. | Stimulation for treating and diagnosing conditions |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20060154938A1 (en) * | 2002-12-27 | 2006-07-13 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
US20060195169A1 (en) * | 2002-11-14 | 2006-08-31 | Yossi Gross | Surgical tools and techniques for stimulation |
US20060240050A1 (en) * | 2003-07-23 | 2006-10-26 | Douglas Pharmaceuticals Limited | Stable clozapine suspension formulation |
US20080033509A1 (en) * | 2002-04-25 | 2008-02-07 | Brainsgate Ltd. | Stimulation of the otic ganglion for treating medical conditions |
US20080051458A1 (en) * | 2006-07-28 | 2008-02-28 | Xuedong Dai | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
US20090299418A1 (en) * | 2004-08-23 | 2009-12-03 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
US20110160623A1 (en) * | 2004-02-20 | 2011-06-30 | Brainsgate Ltd. | External stimulation of the spg |
US7973043B2 (en) | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US9387182B2 (en) | 2002-12-27 | 2016-07-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
WO2017024129A1 (en) * | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
WO2017205666A1 (en) * | 2016-05-25 | 2017-11-30 | National Health Research Institutes | Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
WO2019104179A1 (en) * | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
US10709668B2 (en) | 2015-05-04 | 2020-07-14 | Confluence Pharmaceuticals, Llc | Sprinkle formulations of acamprosate |
US11065222B2 (en) | 2015-02-18 | 2021-07-20 | Aston University | Diagnostic assay and treatment for preeclampsia |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355681B2 (en) * | 1995-12-07 | 2002-03-12 | Glytech, Inc. | Glycine substitutes and precursors for treating a psychosis |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
EP2338482A3 (en) * | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
SK4592001A3 (en) * | 1998-10-16 | 2001-12-03 | Janssen Pharmaceutica Nv | Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
DE19918105C1 (en) * | 1999-04-22 | 2000-09-21 | Lohmann Therapie Syst Lts | Transdermal patch for administering neuroleptic agent i.e. fluphenazine, flupentixol or triflupromazine, includes matrix layer containing penetration enhancer and hydrocarbon polymer |
EP2210598B1 (en) | 2000-08-25 | 2013-09-18 | Research Corporation Technologies, Inc. | Anticonvulsant amino acids for the treatment of pain |
US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
US20050059743A1 (en) * | 2000-11-01 | 2005-03-17 | Sention, Inc. | Methods for treating mild cognitive impairment and alzheimer's disease |
CA2427388C (en) * | 2000-11-01 | 2011-12-20 | Sention, Inc. | Pharmaceutical compositions and uses for improving memory and learning impairments |
US20030232890A1 (en) * | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
US7619005B2 (en) * | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
US20070117869A1 (en) * | 2000-11-01 | 2007-05-24 | Cognition Pharmaceuticals Llc | Methods for treating coginitive impairment and improving cognition |
WO2002043507A2 (en) * | 2000-11-30 | 2002-06-06 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
WO2002078629A2 (en) * | 2001-03-29 | 2002-10-10 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
WO2005016319A2 (en) * | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
EP1935414A3 (en) * | 2001-05-02 | 2010-08-18 | Blanchette Rockefeller Neurosciences Institute | Carbonic anhydrase activators for enhancig learning and memory |
JP4824268B2 (en) * | 2001-05-02 | 2011-11-30 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Carbonic anhydrase activator for enhancing learning and memory |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
JP2005503425A (en) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | Delivery of drug ester by the prescribed inhalation route |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
BE1015608A6 (en) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | TREATMENT arteritis. |
EP1475090A4 (en) * | 2002-02-14 | 2007-08-08 | Ajinomoto Kk | Drugs for mitochondrial diseases |
JP2005527525A (en) * | 2002-03-15 | 2005-09-15 | ハー・ルンドベック・アクチエゼルスカベット | Methods of using asc-1 inhibitors for the treatment of neurological and psychiatric disorders |
EP1512013A2 (en) * | 2002-06-10 | 2005-03-09 | EVOTEC Neurosciences GmbH | Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases |
US20050164400A1 (en) * | 2002-07-04 | 2005-07-28 | Kenji Hashimoto | Method of examining and diagnosing integration dysfunction syndrome |
FR2843590B1 (en) * | 2002-08-14 | 2007-10-05 | Prestwick Scient Capital Inc | DERIVATIVES OF R (+) - 2-AMINO-3-HYDROXYPROPANOIC ACID WITH GLYCINERGIC ACTION |
EP1535616B1 (en) | 2002-08-22 | 2009-05-13 | Dainippon Sumitomo Pharma Co., Ltd. | Remedy for integration dysfunction syndrome |
US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
AU2003267788A1 (en) * | 2002-10-25 | 2004-05-13 | Pfizer Products Inc. | Novel injectable depot formulations |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US20070249537A1 (en) * | 2003-01-23 | 2007-10-25 | Supernus Pharmaceuticals, Inc. | Absorption enhancing agents |
IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
DK1615632T3 (en) * | 2003-04-17 | 2007-04-10 | Jallal Messadek | Liquid oral forms for controlled excretion of betaine |
WO2004100954A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Treatment of psychotic and depressive disorders |
ES2370395T3 (en) | 2003-05-21 | 2011-12-15 | Alexza Pharmaceuticals, Inc. | USE OF A SOLID FUEL LAYER, MANUFACTURING PROCEDURE AND CORRESPONDING HEATING UNIT. |
WO2004112700A2 (en) * | 2003-06-06 | 2004-12-29 | The General Hospital Corporation | Methods and compositions for modulating amyloid precursor protein translation |
JP4624261B2 (en) | 2003-06-23 | 2011-02-02 | 大日本住友製薬株式会社 | Treatment for senile dementia |
US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US20060128657A1 (en) * | 2003-08-04 | 2006-06-15 | Jallal Messadek | Selected betaines and their uses |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
WO2005053703A1 (en) * | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
CA2550650A1 (en) * | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
US20120225916A1 (en) * | 2003-12-29 | 2012-09-06 | Mcdevitt Jason P | Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine |
RU2006127475A (en) | 2003-12-29 | 2008-02-10 | Джейсон МАКДЭВИТТ (US) | COMPOSITIONS AND METHODS OF TREATMENT OF RETRIDGING MEDICAL CONDITIONS |
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
WO2005080976A1 (en) | 2004-02-20 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
CA2609972C (en) * | 2004-03-22 | 2013-05-14 | Apkarian Technologies Llc | Method and compositions for treatment of chronic neuropathic pain |
TW200538181A (en) | 2004-05-18 | 2005-12-01 | Brni Neurosciences Inst | Treatment of depressive disorders |
WO2005115471A2 (en) * | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
JP2008504295A (en) * | 2004-06-25 | 2008-02-14 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalaninemia |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
WO2006023702A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
WO2006034196A1 (en) * | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
WO2006060186A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives for the treatment of dementia and related disorders |
DE602005019203D1 (en) * | 2004-12-16 | 2010-03-18 | Janssen Pharmaceutica Nv | COMBINATION OF A GLYCIN TRANSPORTER (GLYT1) HEMMER AND AN ANTIPSYCHOTIC TO TREAT SYMPTOMS OF SCHIZOPHRENIA AND THEIR PREPARATION AND USE |
US7655644B2 (en) | 2004-12-21 | 2010-02-02 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
US8163956B2 (en) | 2005-06-13 | 2012-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of GLYT1 transporters |
CA2615147A1 (en) * | 2005-07-14 | 2007-01-18 | The University Of British Columbia | Neuroprotective modulation of nmda receptor subtype activities |
CA2616416A1 (en) * | 2005-09-09 | 2007-05-03 | Labopharm, Inc. | Trazodone composition for once a day adminisitiation |
WO2007041025A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Radiolabeled glycine transporter inhibitors |
KR20080105105A (en) * | 2006-03-24 | 2008-12-03 | 와이어쓰 | Methods for treating cognitive and other disorders |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
US20100129805A1 (en) * | 2006-11-09 | 2010-05-27 | Wai Lun Alan Fung | Slc1a1 antipsychotic drug response markers |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
WO2008118785A2 (en) * | 2007-03-23 | 2008-10-02 | Tikvah Therapeutics | Methods for treating depression using immediate-impact treatments and d-cycloserine |
US20100113453A1 (en) * | 2007-04-10 | 2010-05-06 | Mcdevitt Jason P | Sublingual Formulations of D-Cycloserine and Methods of Using Same |
US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | Improving the tolerability of mirtazapine and a second active by using them in combination |
US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
WO2009018368A1 (en) * | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
EP2111858A1 (en) * | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
GB0817379D0 (en) * | 2008-09-23 | 2008-10-29 | Merck Sharp & Dohme | New use |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20110237537A1 (en) * | 2009-05-29 | 2011-09-29 | Lombard Jay L | Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis |
US20120041066A1 (en) * | 2010-08-16 | 2012-02-16 | Lombard Jay L | Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways |
US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
US20120148509A1 (en) * | 2009-09-14 | 2012-06-14 | Shiseido Company, Ltd. | Composition for alleviating ultraviolet irradiation-induced damage |
TWI544923B (en) * | 2009-12-29 | 2016-08-11 | 何應瑞 | Pharmaceutical compositions for treatment of neurodegenerative disorders |
WO2011104298A1 (en) * | 2010-02-24 | 2011-09-01 | Universität Zürich | Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
WO2012065102A2 (en) * | 2010-11-12 | 2012-05-18 | Promentis Pharmaceuticals, Inc. | S-t-butyl protected cysteine di-peptide analogs and related compounds |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
WO2012104852A1 (en) * | 2011-01-31 | 2012-08-09 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
JP6265908B2 (en) | 2011-11-21 | 2018-01-24 | ザ インスティチュート フォー エスノメディシン | L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
KR101499299B1 (en) * | 2012-08-03 | 2015-03-09 | 연세대학교 산학협력단 | Autism model mouse by Shank2 gene deletion and the use thereof |
AU2013299656C1 (en) * | 2012-08-07 | 2017-06-22 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
AT514349B1 (en) * | 2013-06-12 | 2018-05-15 | Red Bull Gmbh | Alpha-alkylated amino acids (AAAAs) |
WO2015031493A1 (en) * | 2013-08-27 | 2015-03-05 | The Johns Hopkins University | Amino acid treatment of seizures |
US9877951B2 (en) | 2015-02-12 | 2018-01-30 | College Of William And Mary | Method for treating dementia |
US20170143681A1 (en) | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
CN105476976B (en) * | 2015-12-22 | 2018-09-25 | 广州瑞尔医药科技有限公司 | Pharmaceutical composition and its preparation method and application |
US9877942B1 (en) * | 2017-02-13 | 2018-01-30 | Syneurx International (Taiwan) Corp. | Co-crystals of substituted glycine and uses thereof |
AU2018274765A1 (en) * | 2017-05-25 | 2020-01-23 | Glytech Llc. | Formulations for treatment of post-traumatic stress disorder |
US10226442B2 (en) * | 2017-07-10 | 2019-03-12 | Syneurx International (Taiwan) Corp. | Lithium salts of N-substituted glycine compounds and uses thereof |
KR101952443B1 (en) * | 2018-08-23 | 2019-02-26 | 주식회사 아스트로젠 | Novel magnesium-serinate compound and use thereof |
EP4241774A1 (en) * | 2020-11-04 | 2023-09-13 | Gliacelltech Inc. | Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine |
WO2023171106A1 (en) * | 2022-03-08 | 2023-09-14 | ソシウム株式会社 | Agent for suppressing aggregation of tdp-43, agent for suppressing cell death of cells in which tdp-43 is overexpressed, and agent for preventing or treating diseases associated with aggregation of tdp-43 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3873722A (en) | 1974-05-31 | 1975-03-25 | Nelson Res & Dev | Method for treating schizophrenia |
JPS5520747A (en) * | 1978-08-01 | 1980-02-14 | Sumitomo Chem Co Ltd | Antidepressant |
US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
US5468763A (en) | 1987-12-01 | 1995-11-21 | G. D. Searle & Co. | Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder |
US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
US5015740A (en) | 1988-08-05 | 1991-05-14 | Janssen Pharmaceutica N.V. | Antipsychotic 3-piperazinylbenzazole derivatives |
US5187171A (en) | 1989-01-09 | 1993-02-16 | G. D. Searle & Co. | Use of a glycine b partial agonist as an antipsychotic |
US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
JPH03236315A (en) * | 1989-12-05 | 1991-10-22 | Nippon Oil & Fats Co Ltd | Antipsychotic agent |
US5260324A (en) | 1990-02-06 | 1993-11-09 | G. D. Searle & Company | Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
DE4117629A1 (en) * | 1991-05-29 | 1992-12-03 | Max Planck Gesellschaft | Use of phosphatidyl serine derivs. - for treatment of depression and loss of cerebral function e.g. Parkinson's disease and Alzheimer's disease |
DE69315920T2 (en) | 1992-09-04 | 1998-06-10 | Takeda Chemical Industries Ltd | Condensed heterocyclic compounds, their production and use |
GB9300051D0 (en) | 1993-01-04 | 1993-03-03 | Merck Sharp & Dohme | Therapeutic agents |
EP0696586A1 (en) * | 1993-04-27 | 1996-02-14 | Yamanouchi Pharmaceutical Co. Ltd. | Serine derivative |
JPH0826986A (en) * | 1994-07-21 | 1996-01-30 | Yamanouchi Pharmaceut Co Ltd | Antiphencyclidine agent |
RU2096044C1 (en) | 1995-07-19 | 1997-11-20 | Малое предприятие "Ветта" | Veterinary implantable preparation for regulation of biological rhythm in animals |
PT871440E (en) | 1995-12-07 | 2006-07-31 | Daniel C Javitt | TREATMENT OF NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA WITH ANTAGONISTS OF GLYCINE CAPTACAO |
US6355681B2 (en) | 1995-12-07 | 2002-03-12 | Glytech, Inc. | Glycine substitutes and precursors for treating a psychosis |
US6361957B1 (en) | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
HUP0100815A3 (en) * | 1996-05-31 | 2002-11-28 | Allelix Neuroscience Inc South | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
EP2338482A3 (en) | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
AU760769B2 (en) | 1998-05-23 | 2003-05-22 | Altana Pharma Ag | Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity |
US6551993B1 (en) | 1999-08-16 | 2003-04-22 | Thomas Jefferson University | Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction |
-
1999
- 1999-04-14 EP EP10075625A patent/EP2338482A3/en not_active Withdrawn
- 1999-04-14 WO PCT/US1999/008056 patent/WO1999052519A2/en active IP Right Grant
- 1999-04-14 IL IL13900899A patent/IL139008A0/en not_active IP Right Cessation
- 1999-04-14 AU AU35571/99A patent/AU765603C/en not_active Expired
- 1999-04-14 NZ NZ508160A patent/NZ508160A/en not_active IP Right Cessation
- 1999-04-14 CA CA2601132A patent/CA2601132C/en not_active Expired - Lifetime
- 1999-04-14 PT PT99917453T patent/PT1073432E/en unknown
- 1999-04-14 DE DE1073432T patent/DE1073432T1/en active Pending
- 1999-04-14 JP JP2000543129A patent/JP2002511409A/en active Pending
- 1999-04-14 RU RU2000128654/14A patent/RU2219924C2/en active
- 1999-04-14 DK DK99917453T patent/DK1073432T3/en active
- 1999-04-14 CA CA002328197A patent/CA2328197C/en not_active Expired - Lifetime
- 1999-04-14 AT AT99917453T patent/ATE369848T1/en active
- 1999-04-14 EP EP07075595A patent/EP1844769A3/en not_active Withdrawn
- 1999-04-14 EP EP99917453A patent/EP1073432B1/en not_active Expired - Lifetime
- 1999-04-14 HU HU0101627A patent/HUP0101627A3/en unknown
- 1999-04-14 US US09/291,296 patent/US6228875B1/en not_active Expired - Lifetime
- 1999-04-14 DE DE69936848T patent/DE69936848T2/en not_active Expired - Lifetime
- 1999-04-14 ES ES99917453T patent/ES2164040T3/en not_active Expired - Lifetime
-
2001
- 2001-04-13 US US09/834,351 patent/US6420351B1/en not_active Expired - Lifetime
- 2001-08-07 HK HK01105482A patent/HK1036583A1/en unknown
-
2002
- 2002-07-15 US US10/196,686 patent/US6667297B2/en not_active Expired - Lifetime
-
2003
- 2003-09-23 US US10/668,583 patent/US6974821B2/en not_active Expired - Lifetime
-
2005
- 2005-07-05 US US11/175,832 patent/US7704978B2/en not_active Expired - Lifetime
-
2007
- 2007-10-02 CY CY20071101253T patent/CY1106898T1/en unknown
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050159790A1 (en) * | 2000-05-08 | 2005-07-21 | Brainsgate Ltd. | Stimulation for treating and diagnosing conditions |
US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
US20030185754A1 (en) * | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
US7396542B2 (en) | 2001-12-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
US7357945B2 (en) | 2001-12-28 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
US20080187584A1 (en) * | 2001-12-28 | 2008-08-07 | Teva Pharmaceuticals Usa, Inc. | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
US7138137B2 (en) | 2001-12-28 | 2006-11-21 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
US20030158230A1 (en) * | 2001-12-28 | 2003-08-21 | Rakefet Cohen | Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
US20080033509A1 (en) * | 2002-04-25 | 2008-02-07 | Brainsgate Ltd. | Stimulation of the otic ganglion for treating medical conditions |
US20030235177A1 (en) * | 2002-06-19 | 2003-12-25 | Yeon-Chun Park | Composite access point apparatus, and method for processing voice/data packets using the same |
US7973043B2 (en) | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
US7160913B2 (en) | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
US20070129412A1 (en) * | 2002-09-13 | 2007-06-07 | Thomas Jefferson University | Methods for treating parkinson's disease |
US20040087596A1 (en) * | 2002-09-13 | 2004-05-06 | Schneider Jay S. | Methods and kit for treating Parkinson's disease |
US20100049230A1 (en) * | 2002-11-14 | 2010-02-25 | Brainsgate Ltd. | Greater palatine canal stylet |
US20060195169A1 (en) * | 2002-11-14 | 2006-08-31 | Yossi Gross | Surgical tools and techniques for stimulation |
US8229571B2 (en) | 2002-11-14 | 2012-07-24 | Brainsgate Ltd. | Greater palatine canal stylet |
US9694009B2 (en) | 2002-12-27 | 2017-07-04 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
US8759350B2 (en) | 2002-12-27 | 2014-06-24 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
US20060154938A1 (en) * | 2002-12-27 | 2006-07-13 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
US9387182B2 (en) | 2002-12-27 | 2016-07-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
US20060240050A1 (en) * | 2003-07-23 | 2006-10-26 | Douglas Pharmaceuticals Limited | Stable clozapine suspension formulation |
US8057811B2 (en) | 2003-07-23 | 2011-11-15 | Douglas Pharmaceuticals Limited | Stable clozapine suspension formulation |
US20050118286A1 (en) * | 2003-10-30 | 2005-06-02 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8954149B2 (en) | 2004-02-20 | 2015-02-10 | Brainsgate Ltd. | External stimulation of the SPG |
US20110160623A1 (en) * | 2004-02-20 | 2011-06-30 | Brainsgate Ltd. | External stimulation of the spg |
US7875632B2 (en) | 2004-05-21 | 2011-01-25 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050288328A1 (en) * | 2004-05-21 | 2005-12-29 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7863296B2 (en) | 2004-05-21 | 2011-01-04 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20090299418A1 (en) * | 2004-08-23 | 2009-12-03 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8406869B2 (en) | 2005-08-19 | 2013-03-26 | Brainsgate, Ltd. | Post-acute electrical stimulation treatment of adverse cerebrovascular events |
US8958881B2 (en) | 2005-08-19 | 2015-02-17 | Brainsgate Ltd. | Neuroprotective electrical stimulation |
US7799829B2 (en) | 2006-07-28 | 2010-09-21 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
US20090192225A1 (en) * | 2006-07-28 | 2009-07-30 | Xenoport, Inc. | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use |
US7531572B2 (en) | 2006-07-28 | 2009-05-12 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
US20080051458A1 (en) * | 2006-07-28 | 2008-02-28 | Xuedong Dai | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US10512771B2 (en) | 2013-11-10 | 2019-12-24 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US11065222B2 (en) | 2015-02-18 | 2021-07-20 | Aston University | Diagnostic assay and treatment for preeclampsia |
US10709668B2 (en) | 2015-05-04 | 2020-07-14 | Confluence Pharmaceuticals, Llc | Sprinkle formulations of acamprosate |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
WO2017024129A1 (en) * | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
CN109475500A (en) * | 2016-05-25 | 2019-03-15 | 财团法人卫生研究院 | The method and composition of psychiatric symptoms side effect and habituation illness are caused for lowering ketamine |
TWI648049B (en) * | 2016-05-25 | 2019-01-21 | National Health Research Institutes | Methods and compositions for reducing psychotic side effects and addiction disorders of K-life |
WO2017205666A1 (en) * | 2016-05-25 | 2017-11-30 | National Health Research Institutes | Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine |
US11213495B2 (en) | 2016-05-25 | 2022-01-04 | National Health Research Institutes | Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine |
IL263153B1 (en) * | 2016-05-25 | 2023-05-01 | National Health Res Inst | Method and composition for decreasing the pschotomimetic and addictive disorder of ketamine |
IL263153B2 (en) * | 2016-05-25 | 2023-09-01 | National Health Res Inst | Method and composition for decreasing the pschotomimetic and addictive disorder of ketamine |
WO2019104179A1 (en) * | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
US10668036B2 (en) * | 2017-11-22 | 2020-06-02 | Concert Pharmaceuticals, Inc. | Deuterated analogs of D-serine and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6974821B2 (en) | Methods for treating neuropsychiatric disorders | |
US10265278B2 (en) | Pharmaceutical compositions and methods utilizing a D-amino acid | |
WO2009018368A1 (en) | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders | |
AU2008220668A1 (en) | Treatment of anxiety disorders with minocycline | |
US9504665B2 (en) | High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders | |
CA3065003A1 (en) | Formulations for treatment of post-traumatic stress disorder | |
AU2008281016A1 (en) | Novel combinations of neramexane for the treatment of neurodegenerative disorders | |
MXPA00010009A (en) | Methods for treating neuropsychiatric disorders | |
CA3076180C (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
US20060094709A1 (en) | Methods for the treatment of bipolar disorder using carbamazepine | |
US20050124601A1 (en) | Methods for the treatment of bipolar disorder using carbamazepine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: GENERAL HOSPITAL CORPORATION, THE, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSAI, GUOCHUAN;COYLE, JOSEPH;REEL/FRAME:020222/0369;SIGNING DATES FROM 19990609 TO 19990610 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
SULP | Surcharge for late payment | ||
FPAY | Fee payment |
Year of fee payment: 12 |